BRCA2 Pathogenic Variants Linked to Secondary Cancers
In triple-negative breast cancer, patients with BRCA2 pathogenic variants had higher frequencies of bone and CNS metastases....
Breast Cancer Oncology
Authoritative medical articles, news, research, and guidelines pertaining to Breast Cancer Oncology.
For Survivors of Breast Cancer, Chronic Pain Greatly Reduces QOL
In survivors of breast cancer, the influence of chronic pain on QOL persisted even after controlling for concurrent pain. Chronic pain remains highly prevalent among survivors o...
Ultrasound Screening Focuses on Women With Dense Breasts, Regardless of Risk
Other breast cancer risk factors in addition to breast density should be considered when deciding whether to prescribe supplemental ultrasound screening....
Mammography AI Improves Prediction of Breast Cancer
Mammography AI scores, along with traditional risk factors, can potentially identify up to 60% of women at higher risk for breast cancer. Breast cancer is the second leading cau...
Lifestyle Changes Are Key After Treatment for High-Risk Breast Cancer
Patients with the strongest versus weakest adherence to the cancer prevention lifestyle recommendations experienced a 58% reduction in mortality. “Although the American Instit...
Adjuvant Ribociclib Improves Invasive Disease-Free Survival in Early Breast Cancer
Adding ribociclib to endocrine therapy improved invasive and distant disease-free survival of patients with early-stage HR-positive/HER2-negative breast cancer. Most breast cancers ar...
SONIA: No Survival Benefit of First-Line CDK4/6 Inhibition in Metastatic Breast Cancer
First-line CDK4/6 inhibition did not boost survival or QOL but did prolong CDK4/6 inhibitor use and increased grade 3-4 toxicity and drug costs. CDK4/6 inhibitors improve the outcome ...
Gene Expression Profiles Predict Benefit From Neoadjuvant Immune Checkpoint Therapy in Triple-Negative Breast Cancer
The GeparNuevo trial sheds light on the role of RNA expression from peripheral immune cells in predicting treatment outcomes. The phase 2 GeparNuevo trial (NCT02685059) has demonstra...
Reasons to Pair Cervical, Colorectal & Breast Cancer Screenings
Studies have suggested that screening for a given type of cancer could be used to promote participation in other types. Specifically, breast cancer (BC) screening tends to have a higher part...
#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer
Click to read this study in The Lancet Oncology....
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology....
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
Click to read this study in JAMA Network Open. ...
Baseline CTC Count Can Guide First-Line Treatment in HR-Positive/HER-Negative Metastatic Breast Cancer
A single assessment of the circulating tumor cells (CTC) count before treatment can guide the treatment decision between chemotherapy and single-agent endocrine therapy in ER-positive/HER2-n...
Resistance to CDK4/6 Inhibitors Likely Due to Expansion of Pre-Existing Resistant Clones
In vitro studies using DNA barcoded cell lines demonstrated that resistance to CDK4/6 inhibitors is likely due to the expansion of pre-existing resistant clones, suggesting that targeting re...
No Benefit of Palbociclib With Fulvestrant Beyond Progression on Prior CDK4/6 Inhibition
Among patients with HR-positive/HER2-negative metastatic breast cancer, combining palbociclib with fulvestrant beyond progression on prior CDK4/6 inhibition did not significantly improve pro...
Improved Benefit of Elacestrant With Longer Duration of CDK4/6 Inhibition
Duration of first-line CDK4/6 inhibitor therapy in patients with ER-positive/HER2-negative metastatic breast cancer is associated with duration of progression-free survival (PFS) of subseque...
T-DXd Superior Vs Chemotherapy-Based Treatments When Previously Treated With T-DM1
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastati...
Germline Pathogenic Variants for Breast Cancer Also Increase Contralateral Breast Cancer Risk
In women carrying a germline pathogenic variant for breast cancer, like BRCA1, BRCA2, or CHEK2, the risk for contralateral breast cancer is also increased, data from a sub-analysis of the CA...
Anti-PD-1/Anti-LAG-3 Combination Highly Effective in HER2-Negative Breast Cancer
Paclitaxel/cemiplimab/fianlimab is a highly effective combination for neoadjuvant therapy in both triple-negative breast cancer (TNBC) and HR-positive/HER2-negative breast cancer. In additio...
Endocrine Interruption Does Not Impact Short-Term Disease in Breast Cancer
Patients with breast cancer who pause their endocrine therapy to try to get pregnant experienced short-term rates of breast cancer recurrence similar to women who do not pause therapy for pr...
MORE ARTICLES BELOW 
Physician’s Weekly Daily Brief
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.